Changes in drug survival of adalimumab over time in patients with psoriasis: a nationwide cohort study
Clinical and Experimental Dermatology · 17.08.2026 · 51 (9) · 1621-1628
DOI: 10.1093/ced/llag142 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical and Experimental Dermatology, online erschienen am 25.03.2026. Verfasst von Gustav Hjort und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergy, Copenhagen University Hospital, Herlev and Gentofte, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Adalimumab, Psoriasis. Die Arbeit nennt 22 Literaturangaben. Gefördert von: LEO Pharma, Novartis, Janssen.
Abstract (Originalsprache)
Background
Drug survival of older biologic therapies is thought to be influenced by the availability of newer biologic therapies and lower-cost biosimilars. However, there are limited data examining changes in drug survival over time.
Objectives
To examine the drug survival of adalimumab over the past two decades.
Methods
This observational, retrospective, multicentre cohort study analysed data from patients with moderate-to-severe psoriasis treated with adalimumab registered in the Danish nationwide registry, DERMBIO. Patients were stratified into two distinct time periods based on initiation date: an early period (2007–2016) and a late period (2019–2024). Kaplan–Meier curves were used to present unadjusted drug survival curves. A multivariable adjusted Cox proportional hazards model was used to compare the risk of drug discontinuation between the two periods.
Results
In total, 2336 patients were included: 861 in the early period and 1475 in the late period. We found a significantly lower risk of drug discontinuation in the late period compared with the early period (adjusted hazard ratio 0.78, 95% confidence interval 0.68–0.90, P < 0.001), despite the concurrent availability of newer and more effective biologic therapies.
Conclusions
This study found that the increased number of available biologic therapies did not have a negative impact on the drug survival of adalimumab. On the contrary, discontinuation risk was significantly lower in 2019–2024 compared with 2007–2016. The concurrent introduction of lower-cost biosimilars and the associated rise in dose escalation may have contributed to the improved drug survival observed in the later period.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Allergy, Copenhagen University Hospital, Herlev and Gentofte, Copenhagen, Denmark.
- Copenhagen Research Group for Inflammatory Skin, Herlev and Gentofte Hospital, Copenhagen, Denmark.
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
- Department of Dermatology, Zealand University Hospital, Roskilde, Denmark.
- Department of Dermatology, Odense University Hospital, Odense, Denmark.
- Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.
ORCID-Profile: Gustav Hjort, Lone Skov
Förderung
- LEO Pharma
- Novartis
- Janssen
Zitieren
APA
Hjort, G., Schwarz, C. W., Bryld, L. E., Ajgeiy, K. K., Rasmussen, M. K., Bertelsen, T., Hjuler, K. F., Dam, T. N., Loft, N., & Skov, L. (2026). Changes in drug survival of adalimumab over time in patients with psoriasis: a nationwide cohort study. Clinical and Experimental Dermatology, 51(9), 1621-1628. https://doi.org/10.1093/ced/llag142
Vancouver
Hjort G, Schwarz CW, Bryld LE, Ajgeiy KK, Rasmussen MK, Bertelsen T, et al. Changes in drug survival of adalimumab over time in patients with psoriasis: a nationwide cohort study. Clinical and Experimental Dermatology. 2026;51(9):1621-1628. doi:10.1093/ced/llag142
BibTeX
@article{Hjort2026,
author = {Hjort, Gustav and Schwarz, Christopher W and Bryld, Lars Erik and Ajgeiy, Kawa K and Rasmussen, Mads K and Bertelsen, Trine and Hjuler, Kasper F and Dam, Tomas N and Loft, Nikolai and Skov, Lone},
title = {Changes in drug survival of adalimumab over time in patients with psoriasis: a nationwide cohort study},
journal = {Clinical and Experimental Dermatology},
year = {2026},
volume = {51},
number = {9},
pages = {1621--1628},
doi = {10.1093/ced/llag142}
}
EUVIMED